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Purpose: To analyze the potential association of programmed cell death 1 (PDCD1) with Vogt-Koyanagi-Harada (VKH)
syndrome in a Chinese Han population.
Methods: Three single nucleotide polymorphism (SNPs), PD-1.3G/A, PD-1.5C/T, and PD-1.6G/A, were genotyped in
247 VKH patients and 289 age-, sex-, and ethnically-matched healthy controls using polymerase chain reaction-restriction
fragment length polymorphism (PCR-RFLP) assay. The associations of genotypes and alleles with VKH syndrome were
analyzed.
Results: All genotype distributions in healthy controls were in Hardy–Weinberg equilibrium. The genotype and allele
frequencies of PD-1.3, PD-1.5, and PD-1.6 were not different between patients with VKH syndrome and healthy controls.
No significant difference was observed according to the status of human leukocyte antigen (HLA)-DR4 and HLA-DRw53.
Compared to the controls, lower frequencies of the PD-1.5C genotype and allele frequencies were observed in VKH
patients with extraocular findings.
Conclusions: PD-1.3 and PD-1.6 polymorphisms are not associated with the susceptibility to VKH syndrome in the
Chinese Han population. However, PD-1.5 may be negatively associated with the occurrence of extraocular manifestations
of VKH syndrome.
Vogt-Koyanagi-Harada  (VKH)  syndrome  is  an
autoimmune  disease  characterized  by  a  bilateral
granulomatous panuveitis and systemic disorders including
poliosis, vitiligo, alopecia, and central nervous system and
auditory signs [1]. Although the etiology of VKH syndrome
remains  unclear,  several  studies  have  suggested  that  an
autoimmune  response  against  melanocytes  or  tyrosinase
family proteins may play a key role in this disease [2,3].
Genetic predisposition is an important element as evidenced
by familial cases [3] and a strong association with the human
leukocyte antigen (HLA) system [4,5], especially HLA-DR4
and HLA-DRw53. However, the association between VKH
syndrome and the HLA system does not fully explain the
genetic risk for this disease. Moreover, little is known about
the  association  of  non-HLA  genetic  factors  with  VKH
syndrome. Therefore, studies on the disease association with
certain genes involved in the immune response may highlight
the genetic background of VKH syndrome.
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Programmed cell death 1 (PD-1), originally identified as
a molecule linked to in vitro induction of apoptotic cell death
in murine lymphoid cell lines [6], is a member of the cluster
of  differentiation  (CD)28/B7  family.  PD-1  contains  an
immunoreceptor tyrosine-based inhibiting motif (ITIM) and
an immunoreceptor tyrosine-based switch motif (ITSM) [7]
and is transcriptionally induced in activated T cells, B cells,
and myeloid cells [8,9]. As an immunoinhibitory receptor,
PD-1 has been shown to inhibit lymphocyte activation and
cytokine production after interacting with its ligands, PD-L1
(B7-H1)  and  PD-L2  (B7-DC)  [10-12].  The  human  gene
encoding PD-1, i.e., PDCD1, is located on chromosome 2q37.
Studies on  PDCD1 polymorphisms have demonstrated its
association  with  several  autoimmune  diseases  including
systemic  lupus  erythematosus  (SLE)  [13-17],  rheumatoid
arthritis  (RA)  [18],  type  I  diabetes  (TID)  [19],  multiple
sclerosis (MS) [20], ankylosing spondylitis (AS) [21], and
Graves' disease [22], although there are also some conflicting
results [23-27]. Our present study was designed to investigate
the association of PDCD1 single nucleotide polymorphisms
(SNPs) including  PD-1.3, PD-1.5,  and  PD-1.6  with VKH
syndrome in a Chinese Han population.
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386Patients and healthy controls: Two hundred and forty-seven
VKH patients with an average age at onset of 33.6 years (109
female and 138 male) and 289 age-, sex-, ethnically-matched
healthy controls with an average age of 35.4 years (129 female
and 160 male) were enrolled in this study. All patients were
recruited from the Uveitis Study Center of the Sun Yat-sen
University  (Guangzhou,  China)  and  the  First  Affiliated
Hospital, Chongqing Medical University (Chongqing, China)
and  fulfilled  the  First  International  Workshop  criteria  for
VKH disease [28]. These new criteria mainly include bilateral
diffuse choroiditis at early phage and sunset glow funds and
nummular chorioretinal depigmented scars at late phase in
association  with  neurologic,  auditory,  or  integumentary
findings. Additionally but importantly, there is no history of
penetrating  ocular  trauma  or  surgery  preceding  the  initial
onset of uveitis and there is no clinical or laboratory evidence
suggestive  of  other  ocular  disease  entities.  The  clinical
characteristics of the tested VKH patients were summarized
in Table 1. Controls were mainly the accompanying person or
spouses  of  the  patients.  The  local  institutional  ethics
committee approved the study, and written informed consent
was obtained from all the study subjects. Blood samples were
collected in EDTA tubes and kept at −70 °C until use.
Genomic DNA extraction and genotyping: Genomic DNA
was isolated from peripheral blood of patients and controls
using standard proteinase K digestion and phenol-chloroform
extraction. Amplification of the target DNA in PDCD1 was
performed by polymerase chain reaction (PCR). We used
those  primers  previously  determined  by  Ferreuris-Vidal,
Velazquez-Cruz, and Kong (Table 2) [14,17,18]. A 15 μl
reaction mixture, which consisted of 7.5 μl Premix Taq (Ex
Taq  Version;  TaKaRa  Biotechnology  Co.  Ltd.,  Dalian,
China), 50 pmoles primers, and 0.2 μg of genomic DNA, was
amplified by PCR. PCR conditions were as follows: initial
denaturation at 95 °C for 5 min followed by 35 cycles of
denaturation  at  94  °C  for  30  s,  annealing  at  different
temperatures (67 °C for PD-1.3, 60 °C for PD-1.5, and 61 °C
for PD-1.6) for 30 s, extension at 72 °C for 30 s, and a final
extension at 72 °C for 5 min.
The SNPs were genotyped by PCR-restriction fragment
length  polymorphism  (RFLP)  analysis.  PCR  products  of
PD-1.3,  PD-1.5,  and  PD-1.6  polymorphisms  were
respectively  digested  with  2  U  of  PstI  (Fermentas
international  Inc.,  Ontario,  Canada),  Pvu  II  (Fermentas
international Inc.), and Nla III (New England Biolabs, Inc.,
Ontario, Canada) restriction enzymes (Table 2) in a 10 µl
reaction  volume  overnight.  Digestion  products  were
visualized on agarose gels of appropriate concentration and
stained with GoldView™ (SBS Genetech, Beijing, China). To
confirm  the  accuracy  of  the  method  employed,  randomly
selected subjects (20% of all samples) were analyzed by direct
sequencing  (Invitrogen  Biotechnology  Co.,  Guangzhou,
China).  Appropriate  controls  (no  template  and  known
genotype) were included in each typing run. HLA-DR4 and
HLA-DRw53 typing was performed using a PCR sequence
specific primers (SSP) method as previously described [29].
Statistical  analysis:  Hardy–Weinberg  equilibrium  (HWE)
was tested using the χ2 test. Allele frequencies were estimated
by  direct  counting.  Allele  and  genotype  frequencies  were
compared between patients and controls by the χ2 test using
SPSS (version 10.0; SPSS Inc., Chicago, IL). The p values
were  corrected  (pc)  with  the  Bonferroni  correction  by
multiplying with the number of analyses performed. pc<0.05
was considered significant.
TABLE 1. THE NUMBER AND RATIO OF VKH PATIENTS WITH EXTRA-OCULAR CLINICAL FEATURES.
Clinical features
VKH Patients (n=247)
n %
Neck stiffness 101 40.9%
Alopecia 81 32.8%
Poliosis 71 28.7%
Tinnitus 87 35.2%
dysacusis 54 21.9%
Scalp hypersensitivity 39 15.8%
Vitiligo 36 14.6%
TABLE 2. PRIMERS OF SNPS PD-1.3, PD-1.5, AND PD-1.6 AND RESTRICTION ENZYMES USED FOR RFLP ANALYSIS.
Marker
name SNP rs number Location allele Primers
Restriction
enzyme
PD-1.3 7146G/A rs11568821 Intron 4 A 5′-CCCCAGGCAGCAACCTCAAT-3′ PstI
5′-GACCGCAGGCAGGCACATAT-3′
PD-1.5 7785C/T rs2227981 Exon 5 C 5′-GTGCCTGTGTTCTCTGTGGA-3′ Pvu II
5′-CCAAGAGCAGTGTCCATCCT-3′
PD-1.6 8737G/A rs10204525 3′-UTR A 5′-TCAGAAGAGCTCCTGGCTGT-3′ Nla III
5′-GGGGAACGCCTGTACCTT-3′
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METHODSRESULTS
Association analysis of single nucleotide polymorphism and
haplotype: Three SNPs were successfully genotyped in 247
patients with VKH syndrome and 289 healthy controls. Table
3 shows the genotype and allele distribution of these SNPs.
The distribution of genotype frequencies of each SNP in the
healthy controls did not show any significant deviation from
the Hardy–Weinberg equilibrium. The frequency of the C
allele of SNP PD-1.5 tended to be lower in VKH patients than
in healthy controls (71.5% versus 78.0%, p=0.013). However,
no difference was found when the Bonferroni correction was
applied  (pc=0.078,  n=6).  Similarly,  although  a  lower
frequency of SNP PD-1.5CC genotype was observed in VKH
patients  as  compared  with  that  in  healthy  controls,  the
difference  was  not  statistically  significant  following  the
Bonferroni  correction  (p=0.034,  pc=0.306,  n=9).  The
genotype  and  allele  frequencies  of  PD-1.3  and  PD-1.6  in
patients with VKH syndrome were not different from those in
healthy controls. In particular, only the GG genotype and the
G allele of PD-1.3 were identified in all patients and controls.
Haplotype analysis using Haploview software showed no
linkage  disequilibrium  in  the  tested  three  SNPs  in  both
patients with VKH syndrome and healthy controls.
Stratification analysis according to HLA status and clinical
characteristics:  The  frequencies  of  HLA-DR4  and  HLA-
DRw53 were shown to be significantly increased in 231 VKH
patients as compared with those in 289 healthy controls (Table
4). The allele and genotype frequencies of PD-1.3, PD-1.5,
and PD-1.6 were not different between VKH patients and
healthy controls when a stratification analysis was performed
according to the status of HLA-DR4 and HLA-DRw53.
When the genotype frequencies were analyzed according
to the clinical features, our results showed significantly lower
frequencies of PD-1.5CC in VKH patients either with poliosis
or with dysacusis as compared to that observed in healthy
controls.  Concerning  the  allele  frequencies  analyzed
          TABLE 3. GENOTYPE AND ALLELE FREQUENCIES OF SNPS PD-1.3, PD-1.5, AND PD-1.6 IN VKH PATIENTS AND HEALTHY
CONTROLS.
PDCD1 SNPs VKH patients
(%)
Healthy
controls (%) χ2 p pc Odds ratio (95%CI)
PD-1.3
Genotype
GG 247 (100) 289 (100) — — — —
AG — —
AA — —
Allele
G 494 (100) 578 (100) — — — —
A — —
PD-1.5
Genotype
CC 131 (53.0) 176 (60.9) 6.786 0.034 0.306 —
CT 91 (36.8) 99 (34.3)
TT 25 (10.1) 14 (4.8)
Allele
C 353 (71.5) 451 (78.0) 6.132 0.013 0.078 0.705 (0.534–0.930)
T 141 (28.5) 127 (22.0)
PD-1.6
Genotype
AA 124 (50.2) 136 (47.1) 5.171 0.075 — —
AG 108 (43.7) 119 (41.2)
GG 15 (6.1) 34 (11.7)
Allele
A 356 (72.1) 391 (67.6) 2.413 0.12 — 1.232 (0.947–1.603)
G 138 (27.9) 187 (32.4)
The distribution of genotype frequencies of each SNP in the healthy controls did not show significant deviation from the Hardy-
Weinberg equilibrium. The frequency of the C allele and CC genotype of PD-1.5 were lower in VKH patients than in healthy
controls, but the differences were not statistically significant following the Bonferroni correction. The genotype and allele
frequencies of PD-1.3 and PD-1.6 in VKH patients were not different from those in healthy controls. Only the GG genotype
and the G allele of PD-1.3 were identified in all patients and controls
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was found that significantly lower frequencies of the PD-1.5C
allele were associated with VKH patients with extraocular
findings including alopecia, poliosis, dysacusis, and tinnitus
(Table  5).  Neither  PD-1.3  nor  PD-1.6  was  found  to  be
associated  with  any  of  the  extraocular  findings  including
alopecia, poliosis, dysacusis, tinnitus, and neck stiffness.
DISCUSSION
Our results showed that a lower frequency of PD-1.5 genotype
or  allele  was  associated  with  certain  extraocular  findings
within  the  VKH  cohort.  However,  PD-1.3  and  PD-1.6
polymorphism  differences  were  identified  between  VKH
patients and healthy controls.
TABLE 4. HLA-DR4 AND HLA-DRW53 DISTRIBUTIONS OF PATIENTS WITH VKH SYNDROME.
HLA
VKH patients
(n=231)
Normal controls
(n=289) χ2 p
HLA-DR4+ 179 (77.5%) 59 (20.4%) 169.712 0
HLA-DR4- 52 (22.5%) 230 (79.6%)
HLA-DRw53+ 203 (87.9%) 193 (66.8%) 32.07 0
HLA-DRw53- 28 (12.1%) 96 (33.2%)
The frequencies of HLA-DR4 and HLA-DRw53 were significantly increased in 231 VKH patients as compared with those in
289 healthy controls.
TABLE 5. GENOTYPES AND ALLELES FREQUENCIES OF PD-1.5 SNP IN VKH PATIENTS AND HEALTHY CONTROLS ACCORDING TO THE
CLINICAL FEATURES.
Clinical
features
PD-1.5
SNP
VKH
patients
(%)
Healthy
controls
(%) χ2
Odds ratio
(95%CI)
Alopecia CC 37 (45.7) 176 (60.9) 9.083 0.011 0.099
CT 34 (42.0) 99 (34.3)
TT 10(12.3) 14 (4.8)
C 107 (66.0) 451 (78.0) 9.78 0.002 0.016 0.548 (0.375–0.801)
T 55 (34.0) 127 (22.0)
Poliosis CC 27 (38.0) 176 (60.9) 15.454 0 0
CT 34 (47.9) 99 (34.3)
TT 10 (14.1) 14 (4.8)
C 89 (62.7) 451 (78.0) 14.328 0 0 0.473 (0.319–0.700)
T 53 (37.3) 127 (22.0)
Dysacusia CC 24 (44.4) 176 (60.9) 17.172 0.0005 0.0045
CT 19 (35.2) 79 (34.3)
TT 11 (20.4) 14 (4.8)
C 68 (63.0) 451 (78.0) 11.213 0.0001 0.008 0.479 (0.309–0.741)
T 40 (37.0) 127 (22.0)
Tinnitus CC 42 (48.3) 176 (60.9) 9.839 0.007 0.063
CT 33 (37.9) 99 (34.3)
TT 12 (13.8) 14 (4.8)
C 118 (67.8) 451 (78.0) 7.574 0.006 0.048 0.593 (0.408–0.863)
T 56 (32.2) 127 (22.0)
Neck stiffness CC 52 (51.5) 176 (60.9) 8.142 0.017 0.153
CT 36 (35.6) 99 (34.3)
TT 13 (12.9) 14 (4.8)
C 140 (69.3) 451 (78.0) 6.201 0.013 0.078 0.636 (0.445–0.910)
T 62 (30.7) 127 (22.0)
The genotype frequencies of PD-1.5 CC in VKH patients either with poliosis or with dysacusia were lower than that observed
in healthy controls. Within the VKH cohort, significantly lower frequencies of the PD-1.5 C allele were associated with VKH
patients with any one of the extraocular findings including alopecia, poliosis, dysacusia and tinnitus.
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p pcVKH syndrome is a multifactorial disease that may result
from interactions among susceptibility genes, environmental
factors,  and  immunological  responses.  The  association  of
HLA-DR4 and HLADRw53 with VKH syndrome has been
reported in the Chinese [4] and Japanese [5] populations. Our
present study confirmed these observations. The non-HLA
genetic background of the disease has not been completely
understood.  It  is  reported  that  there  are  no  genetic
susceptibilities for the tyrosinase gene family and interferon-
γ in Japanese VKH patients [30,31]. Recently, we reported an
association of cytotoxic T lymphocyte-associated antigen-4
(CTLA-4) genetic polymorphisms with the susceptibility to
VKH syndrome in a Chinese population [32]. PD-1 is an
immunoglobulin (Ig) superfamily member related to CD28
and CTLA-4. One hundred and thirty-five SNPs (found in the
NCBI-Entrez  SNP  database)  have  been  identified  in  the
human  PDCD1  region.  Several  studies  showed  that
polymorphisms  of  PD-1.3,  PD-1.5,  and  PD-1.6  were
associated  with  autoimmune  diseases  [13-22],  although
inconsistent results were also reported [23-27]. In this study,
we tested whether the polymorphisms of these three SNPs
were associated with VKH syndrome in Han Chinese patients.
To ensure the analysis results, the following attempts
were made. First, all genotype distributions of three SNPs in
healthy  controls  were  tested  and  found  to  be  in  Hardy–
Weinberg equilibrium. Second, the controls and patients were
strictly matched according to the places where they were born
to  exclude  the  possible  influence  of  stratification  of  the
population. VKH patients of Chinese Han descendents were
also strictly selected in this study to avoid the influence of
gene background. Third, a total of 247 VKH patients and 289
age-, sex-, ethnically-matched healthy controls were used in
this study, and the number of tested samples was large enough
to avoid a bias of the results. Finally, direct sequencing was
performed to validate the genotype findings.
As genetic interaction between HLA genes and non-HLA
genes may influence the susceptibility to autoimmune disease,
a stratification analysis was performed according to the status
of  HLA-DR4  and  HLA-DRw53.  Unexpectedly,  no
association  with  PDCD1  was  observed  in  HLA-DR4  and
HLA-DRw53 positive or negative VKH patients. As VKH
syndrome affects not only the eye but also skin and hair, we
further analyzed the association of polymorphisms of three
SNPs  with  extraocular  findings  in  VKH  patients.  Lower
frequencies of genotype and allele of PD-1.5 were observed
in VKH patients with any of the extraocular findings including
alopecia, poliosis, dysacusis, or tinnitus. These results seem
to suggest that the genotype and allele of PD-1.5 may possibly
protect VKH patients from extraocular findings.
Several previous studies have shown that there is a large
variation in the frequencies of PDCD1 polymorphisms among
different ethnic groups. In the present study, we found a higher
frequency of the PD-1.5C allele and PD-1.6A allele in Chinese
(78%,  67%,  respectively)  than  in  Swedish  (60%,  8%,
respectively), European American (57%, 11%, respectively),
Mexican (54%, 39%. respectively) and African American
individuals  (42%,  48%,  respectively)  [13].  A  higher
frequency of the PD-1.3A allele was reported in the European
population  (5%–12%)  compared  to  that  observed  in  the
Mexican and African American populations (2%–7%) [13,
16] Interestingly, we did not detect the PD-1.3A allele in either
the healthy controls or the VKH patients in this study, which
is  consistent  with  earlier  results  in  healthy  Hong  Kong
Chinese [18] and Japanese populations [27]. With regards to
the association of PD-1.5 polymorphism with autoimmune
disease, a study by Lee et al. [21] showed that a PD-1.5
polymorphism  was  positively  associated  with  ankylosing
spondylitis in Korean patients. Kong and Iwamoto found that
a  polymorphism  of  PD-1.5  was  not  associated  with
rheumatoid arthritis in Hong Kong Chinese [18] and Japanese
[27] patients.
In  conclusion,  this  study  showed  that  all  genotype
distributions of PD-1.3, PD-1.5, and PD-1.6 in Chinese Han
healthy  controls  were  in  Hardy–Weinberg  equilibrium.
Polymorphisms of PD-1.3 and PD-1.6 were not associated
with the susceptibility to VKH syndrome in a Chinese Han
population. However, a genotype or allele of PD-1.5 was
negatively  associated  with  VKH  patients  having
accompanying extraocular findings. It is not clear whether this
association  is  present  in  other  ethnic  VKH  patients  and
whether other PDCD1 polymorphisms are associated with the
susceptibility to VKH syndrome. More studies are needed to
clarify these issues within the VKH cohort.
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